

# Lucio Ildebrando Cocco

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6800975/lucio-ildebrando-cocco-publications-by-citations.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

233  
papers

9,036  
citations

49  
h-index

85  
g-index

257  
ext. papers

10,089  
ext. citations

5.1  
avg, IF

5.54  
L-index

#	Paper	IF	Citations
233	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. <i>Oncotarget</i> , <b>2011</b> , 2, 135-64	3.3	456
232	Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. <i>Aging</i> , <b>2011</b> , 3, 192-222	5.6	437
231	Multiple roles of phosphoinositide-specific phospholipase C isozymes. <i>BMB Reports</i> , <b>2008</b> , 41, 415-34	5.5	357
230	Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. <i>Blood</i> , <b>2004</b> , 104, 2418-24	2.2	349
229	GSK-3 as potential target for therapeutic intervention in cancer. <i>Oncotarget</i> , <b>2014</b> , 5, 2881-911	3.3	332
228	Nuclear localization and signalling activity of phosphoinositidase C beta in Swiss 3T3 cells. <i>Nature</i> , <b>1992</b> , 358, 242-5	50.4	300
227	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. <i>Oncotarget</i> , <b>2012</b> , 3, 1068-111	3.3	250
226	Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. <i>Oncotarget</i> , <b>2012</b> , 3, 954-87	3.3	214
225	NK cells and cancer. <i>Journal of Immunology</i> , <b>2007</b> , 178, 4011-6	5.3	198
224	Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. <i>Oncotarget</i> , <b>2014</b> , 5, 4603-50	3.3	179
223	The emerging multiple roles of nuclear Akt. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2012</b> , 1823, 2168-78	4.9	134
222	Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. <i>Journal of Cellular Physiology</i> , <b>2011</b> , 226, 2762-81	7	124
221	A role for nuclear phospholipase Cbeta 1 in cell cycle control. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 30520-4	5.4	124
220	Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. <i>Aging</i> , <b>2017</b> , 9, 1477-1536	5.6	112
219	Intranuclear 3Rphosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis?. <i>Cellular Signalling</i> , <b>2006</b> , 18, 1101-7	4.9	112
218	Effects of mutations in Wnt/Ectenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2016</b> , 1863, 2942-2976	4.9	101
217	Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. <i>Advances in Biological Regulation</i> , <b>2015</b> , 59, 65-81	6.2	98

216	Phosphorylation of nuclear phospholipase C beta1 by extracellular signal-regulated kinase mediates the mitogenic action of insulin-like growth factor I. <i>Molecular and Cellular Biology</i> , <b>2001</b> , 21, 2981-90	4.8	96
215	Changes in nuclear inositol phospholipids induced in intact cells by insulin-like growth factor I. <i>Biochemical and Biophysical Research Communications</i> , <b>1989</b> , 159, 720-5	3.4	96
214	PLC and PI3K/Akt/mTOR signalling in disease and cancer. <i>Advances in Biological Regulation</i> , <b>2015</b> , 57, 10-6	6.2	95
213	Rapid changes in phospholipid metabolism in the nuclei of Swiss 3T3 cells induced by treatment of the cells with insulin-like growth factor I. <i>Biochemical and Biophysical Research Communications</i> , <b>1988</b> , 154, 1266-72	3.4	90
212	Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 16811-6	11.5	88
211	Toxicity of antimony trioxide nanoparticles on human hematopoietic progenitor cells and comparison to cell lines. <i>Toxicology</i> , <b>2009</b> , 262, 121-9	4.4	85
210	Phosphoinositide-specific phospholipase C in health and disease. <i>Journal of Lipid Research</i> , <b>2015</b> , 56, 1853-60	6.3	83
209	Nuclear phospholipase C and signaling. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2001</b> , 1530, 1-14	5	79
208	Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis. <i>Advances in Biological Regulation</i> , <b>2015</b> , 57, 75-101	6.2	76
207	Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. <i>Cancer Research</i> , <b>2008</b> , 68, 9394-403	10.1	76
206	The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. <i>Cancer Research</i> , <b>2007</b> , 67, 4287-94	10.1	75
205	The therapeutic potential of mTOR inhibitors in breast cancer. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 82, 1189-1212	3.8	72
204	Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. <i>Cell Cycle</i> , <b>2011</b> , 10, 3003-15	4.7	71
203	The physiological roles of primary phospholipase C. <i>Advances in Biological Regulation</i> , <b>2013</b> , 53, 232-41	6.2	70
202	Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. <i>Oncotarget</i> , <b>2017</b> , 8, 14221-14250	3.3	68
201	Targeting GSK3 and Associated Signaling Pathways Involved in Cancer. <i>Cells</i> , <b>2020</b> , 9,	7.9	67
200	Nuclear inositides: facts and perspectives <b>2004</b> , 101, 47-64		66
199	Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy. <i>Advances in Biological Regulation</i> , <b>2014</b> , 54, 176-96	6.2	64

198	Lamin A Ser404 is a nuclear target of Akt phosphorylation in C2C12 cells. <i>Journal of Proteome Research</i> , <b>2008</b> , 7, 4727-35	5.6	64
197	The protein kinase Akt/PKB regulates both prelamin A degradation and Lmna gene expression. <i>FASEB Journal</i> , <b>2013</b> , 27, 2145-55	0.9	59
196	Involvement of nuclear PLCbeta1 in lamin B1 phosphorylation and G2/M cell cycle progression. <i>FASEB Journal</i> , <b>2009</b> , 23, 957-66	0.9	58
195	Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2016</b> , 1863, 438-448	4.9	56
194	Elevated O-GlcNAcylation promotes colonic inflammation and tumorigenesis by modulating NF- $\kappa$ B signaling. <i>Oncotarget</i> , <b>2015</b> , 6, 12529-42	3.3	56
193	Up-regulation of nuclear PLCbeta1 in myogenic differentiation. <i>Journal of Cellular Physiology</i> , <b>2003</b> , 195, 446-52	7	55
192	Primary phospholipase C and brain disorders. <i>Advances in Biological Regulation</i> , <b>2016</b> , 61, 80-5	6.2	54
191	Molecular Mechanisms Underlying Psychological Stress and Cancer. <i>Current Pharmaceutical Design</i> , <b>2016</b> , 22, 2389-402	3.3	54
190	Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. <i>Journal of Cellular Physiology</i> , <b>2011</b> , 226, 822-31	7	52
189	Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 782-90	2.2	52
188	Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells. <i>Journal of Cellular Physiology</i> , <b>2005</b> , 202, 623-34	7	52
187	Nuclear phospholipase C: involvement in signal transduction. <i>Progress in Lipid Research</i> , <b>2005</b> , 44, 185-206	4.3	51
186	Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 3297-308	12.9	50
185	Inositide-dependent phospholipase C signaling mimics insulin in skeletal muscle differentiation by affecting specific regions of the cyclin D3 promoter. <i>Endocrinology</i> , <b>2007</b> , 148, 1108-17	4.8	49
184	PKCepsilon controls protection against TRAIL in erythroid progenitors. <i>Blood</i> , <b>2006</b> , 107, 508-13	2.2	48
183	Inositol lipid cycle in the nucleus. <i>Cellular Signalling</i> , <b>1994</b> , 6, 481-5	4.9	47
182	Protein kinase C involvement in cell cycle modulation. <i>Biochemical Society Transactions</i> , <b>2014</b> , 42, 1471-6	5.1	45
181	Caspase-dependent cleavage of 170-kDa P-glycoprotein during apoptosis of human T-lymphoblastoid CEM cells. <i>Journal of Cellular Physiology</i> , <b>2006</b> , 207, 836-44	7	42

180	Nuclear diacylglycerol kinase-zeta is a negative regulator of cell cycle progression in C2C12 mouse myoblasts. <i>FASEB Journal</i> , <b>2007</b> , 21, 3297-307	0.9	40
179	Nuclear inositides: PI-PLC signaling in cell growth, differentiation and pathology. <i>Advances in Enzyme Regulation</i> , <b>2009</b> , 49, 2-10		39
178	Ankrd2/ARPP is a novel Akt2 specific substrate and regulates myogenic differentiation upon cellular exposure to H(2)O(2). <i>Molecular Biology of the Cell</i> , <b>2011</b> , 22, 2946-56	3.5	39
177	Expression of phospholipase C beta family isoenzymes in C2C12 myoblasts during terminal differentiation. <i>Journal of Cellular Physiology</i> , <b>2004</b> , 200, 291-6	7	39
176	Molecular characterization of protein kinase C-alpha binding to lamin A. <i>Journal of Cellular Biochemistry</i> , <b>2002</b> , 86, 320-30	4.7	39
175	Advances in targeting signal transduction pathways. <i>Oncotarget</i> , <b>2012</b> , 3, 1505-21	3.3	39
174	Nuclear PLCbeta1 is required for 3T3-L1 adipocyte differentiation and regulates expression of the cyclin D3-cdk4 complex. <i>Cellular Signalling</i> , <b>2009</b> , 21, 926-35	4.9	38
173	Nuclear translocation of PKC $\zeta$ isoenzyme is involved in neurogenic commitment of human neural crest-derived periodontal ligament stem cells. <i>Cellular Signalling</i> , <b>2016</b> , 28, 1631-41	4.9	37
172	Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis. <i>Journal of Cellular Biochemistry</i> , <b>2017</b> , 118, 819-828	4.7	36
171	Targeting the cancer initiating cell: the ultimate target for cancer therapy. <i>Current Pharmaceutical Design</i> , <b>2012</b> , 18, 1784-95	3.3	36
170	Catalytic activity of nuclear PLC-beta(1) is required for its signalling function during C2C12 differentiation. <i>Cellular Signalling</i> , <b>2008</b> , 20, 2013-21	4.9	36
169	Nuclear PLCbeta(1) acts as a negative regulator of p45/NF-E2 expression levels in Friend erythroleukemia cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2002</b> , 1589, 305-10	4.9	35
168	Metformin influences drug sensitivity in pancreatic cancer cells. <i>Advances in Biological Regulation</i> , <b>2018</b> , 68, 13-30	6.2	34
167	Phosphoinositide-specific phospholipase C (PI-PLC) beta1 and nuclear lipid-dependent signaling. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2006</b> , 1761, 509-21	5	34
166	Forebrain-specific ablation of phospholipase C $\beta$ 1 causes manic-like behavior. <i>Molecular Psychiatry</i> , <b>2017</b> , 22, 1473-1482	15.1	33
165	Interleukin 2 activates nuclear phospholipase Cbeta by mitogen-activated protein kinase-dependent phosphorylation in human natural killer cells. <i>FASEB Journal</i> , <b>2001</b> , 15, 1789-91	0.9	33
164	Conformational changes of nuclear chromatin related to phospholipid induced modifications of the template availability. <i>Advances in Enzyme Regulation</i> , <b>1984</b> , 22, 447-64		33
163	Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases. <i>Advances in Biological Regulation</i> , <b>2017</b> , 65, 77-88	6.2	31

162	Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan-2-amine (A443654) in T-cell acute lymphoblastic leukemia. <i>Molecular Pharmacology</i> , <b>2008</b> , 74, 884-95	4.3	31
161	Inositides in the nucleus: presence and characterisation of the isozymes of phospholipase beta family in NIH 3T3 cells. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>1999</b> , 1438, 295-9	5	31
160	Nuclear inositol lipid metabolism: more than just second messenger generation?. <i>Journal of Cellular Biochemistry</i> , <b>2005</b> , 96, 285-92	4.7	30
159	Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy. <i>Current Pharmaceutical Design</i> , <b>2016</b> , 22, 2358-88	3.3	30
158	Nuclear phospholipase C $\beta$ signaling, epigenetics and treatments in MDS. <i>Advances in Biological Regulation</i> , <b>2013</b> , 53, 2-7	6.2	29
157	Nuclear phospholipase C beta1 (PLCbeta1) affects CD24 expression in murine erythroleukemia cells. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 24221-6	5.4	29
156	Nuclear PI-PLC $\beta$ : an appraisal on targets and pathology. <i>Advances in Biological Regulation</i> , <b>2014</b> , 54, 2-11	6.2	28
155	Targeting breast cancer initiating cells: advances in breast cancer research and therapy. <i>Advances in Biological Regulation</i> , <b>2014</b> , 56, 81-107	6.2	28
154	Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis. <i>Advances in Biological Regulation</i> , <b>2017</b> , 63, 32-48	6.2	28
153	Nuclear inositide specific phospholipase C signalling interactions and activity. <i>FEBS Journal</i> , <b>2013</b> , 280, 6311-21	5.7	28
152	Nuclear phosphoinositides and their roles in cell biology and disease. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , <b>2011</b> , 46, 436-57	8.7	28
151	Phosphoinositide signalling in nuclei of Friend cells: DMSO-induced differentiation reduces the association of phosphatidylinositol-transfer protein with the nucleus. <i>Biochemical and Biophysical Research Communications</i> , <b>1997</b> , 230, 302-5	3.4	28
150	Proteomic-based analysis of nuclear signaling: PLCbeta1 affects the expression of the splicing factor SRp20 in Friend erythroleukemia cells. <i>Proteomics</i> , <b>2006</b> , 6, 5725-34	4.8	28
149	Insulin-like growth factor-I-dependent stimulation of nuclear phospholipase C-beta1 activity in Swiss 3T3 cells requires an intact cytoskeleton and is paralleled by increased phosphorylation of the phospholipase. <i>Journal of Cellular Biochemistry</i> , <b>1999</b> , 72, 339-48	4.7	28
148	PLC $\beta$ 1: Potential arbitrator of cancer progression. <i>Advances in Biological Regulation</i> , <b>2018</b> , 67, 179-189	6.2	28
147	PLC- $\beta$ and cell differentiation: An insight into myogenesis and osteogenesis. <i>Advances in Biological Regulation</i> , <b>2017</b> , 63, 1-5	6.2	27
146	Role of CREB transcription factor in c-fos activation in natural killer cells. <i>European Journal of Immunology</i> , <b>2002</b> , 32, 3358-65	6.1	27
145	Identification and chromosomal localisation by fluorescence in situ hybridisation of human gene of phosphoinositide-specific phospholipase C beta(1). <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2000</b> , 1484, 175-82	5	27

144	Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling. <i>Oncotarget</i> , <b>2016</b> , 7, 5521-37	3.3	27
143	Nuclear phospholipase C beta1 and cellular differentiation. <i>Frontiers in Bioscience - Landmark</i> , <b>2008</b> , 13, 2452-63	2.8	27
142	Nuclear phosphoinositides: location, regulation and function. <i>Sub-Cellular Biochemistry</i> , <b>2012</b> , 59, 335-615.5		27
141	Novel roles of androgen receptor, epidermal growth factor receptor, TP53, regulatory RNAs, NF-kappa-B, chromosomal translocations, neutrophil associated gelatinase, and matrix metalloproteinase-9 in prostate cancer and prostate cancer stem cells. <i>Advances in Biological Regulation</i> , <b>2016</b> , 60, 64-87	6.2	26
140	The physiology and pathology of inositide signaling in the nucleus. <i>Journal of Cellular Physiology</i> , <b>2011</b> , 226, 14-20	7	26
139	PKR activity is required for acute leukemic cell maintenance and growth: a role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation. <i>Journal of Cellular Physiology</i> , <b>2009</b> , 221, 232-47		26
138	Expression of phosphoinositide-specific phospholipase C isoenzymes in cultured astrocytes. <i>Journal of Cellular Biochemistry</i> , <b>2007</b> , 100, 952-9	4.7	26
137	Inositides in nuclei of Friend cells: changes of polyphosphoinositide and diacylglycerol levels accompany cell differentiation. <i>Cellular Signalling</i> , <b>1995</b> , 7, 53-6	4.9	26
136	Effect of phospholipids on transcription and ribonucleoprotein processing in isolated nuclei. <i>Advances in Enzyme Regulation</i> , <b>1986</b> , 25, 425-38		26
135	Nuclear PLCs affect insulin secretion by targeting PPAR $\alpha$ in pancreatic $\beta$ cells. <i>FASEB Journal</i> , <b>2012</b> , 26, 203-10	0.9	25
134	Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. <i>Advances in Biological Regulation</i> , <b>2019</b> , 71, 172-182	6.2	25
133	Nuclear inositide signaling and cell cycle. <i>Advances in Biological Regulation</i> , <b>2018</b> , 67, 1-6	6.2	25
132	Nuclear Phosphatidylinositol Signaling: Focus on Phosphatidylinositol Phosphate Kinases and Phospholipases C. <i>Journal of Cellular Physiology</i> , <b>2016</b> , 231, 1645-55	7	24
131	Inositol lipid cycle and autonomous nuclear signalling. <i>Advances in Enzyme Regulation</i> , <b>1996</b> , 36, 101-14		24
130	Nuclear phospholipase C signaling through type 1 IGF receptor and its involvement in cell growth and differentiation. <i>Anticancer Research</i> , <b>2005</b> , 25, 2039-41	2.3	24
129	Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. <i>Critical Reviews in Oncology/Hematology</i> , <b>2013</b> , 88, 231-45	7	23
128	K562 cell proliferation is modulated by PLC $\beta$ through a PKC $\epsilon$ mediated pathway. <i>Cell Cycle</i> , <b>2013</b> , 12, 1713-21	4.7	23
127	Inositides in the nucleus: regulation of nuclear PI-PLC $\beta$ 1. <i>Advances in Enzyme Regulation</i> , <b>2002</b> , 42, 181-93		23



126	Nuclear inositol lipid signaling. <i>Advances in Enzyme Regulation</i> , <b>2001</b> , 41, 361-84		23
125	Real-time PCR as a tool for quantitative analysis of PI-PLC $\beta$ 1 gene expression in myelodysplastic syndrome. <i>International Journal of Molecular Medicine</i> , <b>2006</b> , 18, 267-71	4.4	23
124	Nuclear Inositide Signaling Via Phospholipase C. <i>Journal of Cellular Biochemistry</i> , <b>2017</b> , 118, 1969-1978	4.7	22
123	An increased expression of PI-PLC $\beta$ is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes. <i>Journal of Leukocyte Biology</i> , <b>2015</b> , 98, 769-80	6.5	22
122	Nuclear Localization of Diacylglycerol Kinase Alpha in K562 Cells Is Involved in Cell Cycle Progression. <i>Journal of Cellular Physiology</i> , <b>2017</b> , 232, 2550-2557	7	22
121	Prohibitin 2 represents a novel nuclear AKT substrate during all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells. <i>FASEB Journal</i> , <b>2014</b> , 28, 2009-19	0.9	22
120	Nuclear inositide signaling in myelodysplastic syndromes. <i>Journal of Cellular Biochemistry</i> , <b>2010</b> , 109, 1065-71	4.7	22
119	Expression of signal transduction proteins during the differentiation of primary human erythroblasts. <i>Journal of Cellular Physiology</i> , <b>2005</b> , 202, 831-8	7	22
118	BMP-2 Induced Expression of PLC $\beta$ That is a Positive Regulator of Osteoblast Differentiation. <i>Journal of Cellular Physiology</i> , <b>2016</b> , 231, 623-9	7	22
117	Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cells-Power of nutraceuticals. <i>Advances in Biological Regulation</i> , <b>2018</b> , 67, 190-211	6.2	21
116	eEF1A phosphorylation in the nucleus of insulin-stimulated C2C12 myoblasts: Ser $\beta$ is a novel substrate for protein kinase C $\beta$ . <i>Molecular and Cellular Proteomics</i> , <b>2010</b> , 9, 2719-28	7.6	21
115	Significance of subnuclear localization of key players of inositol lipid cycle. <i>Advances in Enzyme Regulation</i> , <b>2004</b> , 44, 51-60		21
114	Revisiting nuclear phospholipase C signalling in MDS. <i>Advances in Biological Regulation</i> , <b>2012</b> , 52, 2-6	6.2	20
113	A role for PLC $\beta$ in myotonic dystrophies type 1 and 2. <i>FASEB Journal</i> , <b>2012</b> , 26, 3042-8	0.9	20
112	Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. <i>Advances in Biological Regulation</i> , <b>2018</b> , 69, 16-34	6.2	20
111	Modulation of nuclear PI-PLC $\beta$ 1 during cell differentiation. <i>Advances in Biological Regulation</i> , <b>2016</b> , 60, 1-5	6.2	19
110	Cancer therapy and treatments during COVID-19 era. <i>Advances in Biological Regulation</i> , <b>2020</b> , 77, 100739	6.2	19
109	Novel 2Rsubstituted, 3Rdeoxy-phosphatidyl-myo-inositol analogues reduce drug resistance in human leukaemia cell lines with an activated phosphoinositide 3-kinase/Akt pathway. <i>British Journal of Haematology</i> , <b>2004</b> , 126, 574-82	4.5	18



108	Molecular characterization of the human PLC beta1 gene. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2002</b> , 1584, 46-54	5	18
107	PLC-beta 1 regulates the expression of miR-210 during mithramycin-mediated erythroid differentiation in K562 cells. <i>Oncotarget</i> , <b>2014</b> , 5, 4222-31	3.3	18
106	Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation. <i>Current Pharmaceutical Design</i> , <b>2016</b> , 22, 2345-8	3.3	18
105	Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes. <i>Leukemia</i> , <b>2019</b> , 33, 2276-2290	10.7	17
104	Phosphoinositide-Dependent Signaling in Cancer: A Focus on Phospholipase C Isozymes. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	17
103	A role for PKR in hematologic malignancies. <i>Journal of Cellular Physiology</i> , <b>2010</b> , 223, 572-91	7	17
102	Nuclear diacylglycerol kinase-theta is activated in response to nerve growth factor stimulation of PC12 cells. <i>Cellular Signalling</i> , <b>2004</b> , 16, 1263-71	4.9	17
101	Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy. <i>Mini-Reviews in Medicinal Chemistry</i> , <b>2014</b> , 14, 873-883	3.2	17
100	Nuclear translocation of PKC- $\zeta$ s associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs). <i>FASEB Journal</i> , <b>2018</b> , 32, 681-692	0.9	16
99	Roles of p53, NF- $\kappa$ B and the androgen receptor in controlling NGAL expression in prostate cancer cell lines. <i>Advances in Biological Regulation</i> , <b>2018</b> , 69, 43-62	6.2	16
98	Phosphoinositide-specific phospholipase C $\zeta$ b (PI-PLC $\zeta$ b) interactome: affinity purification-mass spectrometry analysis of PI-PLC $\zeta$ b with nuclear protein. <i>Molecular and Cellular Proteomics</i> , <b>2013</b> , 12, 2220-35	7.6	16
97	Physiology and pathology of nuclear phospholipase C $\zeta$ . <i>Advances in Enzyme Regulation</i> , <b>2011</b> , 51, 2-12		16
96	Inositide signaling in the nucleus: from physiology to pathology. <i>Advances in Enzyme Regulation</i> , <b>2010</b> , 50, 2-11		16
95	Nuclear phospholipase C beta1, regulation of the cell cycle and progression of acute myeloid leukemia. <i>Advances in Enzyme Regulation</i> , <b>2005</b> , 45, 126-35		16
94	A novel DAG-dependent mechanism links PKC $\zeta$ and Cyclin B1 regulating cell cycle progression. <i>Oncotarget</i> , <b>2014</b> , 5, 11526-40	3.3	16
93	Nuclear phospholipase C isoenzyme imbalance leads to pathologies in brain, hematologic, neuromuscular, and fertility disorders. <i>Journal of Lipid Research</i> , <b>2019</b> , 60, 312-317	6.3	16
92	Netrin-1/DCC-mediated PLC $\zeta$ 1 activation is required for axon guidance and brain structure development. <i>EMBO Reports</i> , <b>2018</b> , 19,	6.5	16
91	Nuclear lipid-dependent signal transduction in human osteosarcoma cells. <i>Advances in Enzyme Regulation</i> , <b>1997</b> , 37, 351-75		15

90	Inositides in the nucleus: taking stock of PLC beta 1. <i>Advances in Enzyme Regulation</i> , <b>1998</b> , 38, 351-63		15
89	Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells. <i>Oncotarget</i> , <b>2017</b> , 8, 76525-76557	3.3	15
88	Identification of the PKR nuclear interactome reveals roles in ribosome biogenesis, mRNA processing and cell division. <i>Journal of Cellular Physiology</i> , <b>2014</b> , 229, 1047-60	7	14
87	Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. <i>Advances in Biological Regulation</i> , <b>2013</b> , 53, 146-55	6.2	14
86	A role for PKCepsilon during C2C12 myogenic differentiation. <i>Cellular Signalling</i> , <b>2010</b> , 22, 629-35	4.9	14
85	Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit. <i>Journal of Cellular Physiology</i> , <b>2019</b> , 234, 11188-11199	7	14
84	AKT-dependent phosphorylation of the adenosine deaminases ADAR-1 and -2 inhibits deaminase activity. <i>FASEB Journal</i> , <b>2019</b> , 33, 9044-9061	0.9	13
83	Phosphoinositide 3 Kinase Signaling in Human Stem Cells from Reprogramming to Differentiation: A Tale in Cytoplasmic and Nuclear Compartments. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	13
82	Signal transduction within the nucleus: revisiting phosphoinositide inositide-specific phospholipase Cbeta1. <i>Advances in Enzyme Regulation</i> , <b>2006</b> , 46, 2-11		13
81	Cbl competitively inhibits epidermal growth factor-induced activation of phospholipase C-gamma1. <i>Molecules and Cells</i> , <b>2003</b> , 15, 245-55	3.5	13
80	Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes. <i>Expert Opinion on Therapeutic Targets</i> , <b>2016</b> , 20, 677-87	6.4	12
79	Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes. <i>Current Pharmaceutical Design</i> , <b>2016</b> , 22, 2349-57	3.3	12
78	Phospholipase C- $\beta$ interacts with cyclin E in adipose- derived stem cells osteogenic differentiation. <i>Advances in Biological Regulation</i> , <b>2019</b> , 71, 1-9	6.2	12
77	Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines. <i>Aging</i> , <b>2020</b> , 12, 10194-10210	5.6	11
76	Reverse-phase protein microarrays (RPPA) as a diagnostic and therapeutic guide in multidrug resistant leukemia. <i>International Journal of Oncology</i> , <b>2011</b> , 38, 427-35	4.4	10
75	Nuclear phospholipase C in biological control and cancer. <i>Critical Reviews in Eukaryotic Gene Expression</i> , <b>2011</b> , 21, 291-301	1.3	10
74	Foreword: "The PI3-kinase/Akt pathway: From signaling to diseases". <i>Advances in Biological Regulation</i> , <b>2015</b> , 59, 1-3	6.2	9
73	Quantitative profiling of the endonuclear glycerophospholipidome of murine embryonic fibroblasts. <i>Journal of Lipid Research</i> , <b>2016</b> , 57, 1492-506	6.3	9

72	Phospholipase C- $\beta$ potentiates glucose-stimulated insulin secretion. <i>FASEB Journal</i> , <b>2019</b> , 33, 10668-10679	9	9
71	Nuclear inositol lipid cycle and differentiation. <i>Advances in Enzyme Regulation</i> , <b>1995</b> , 35, 23-33		9
70	Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling. <i>Advances in Biological Regulation</i> , <b>2020</b> , 78, 100758	6.2	9
69	Endoscopic endonasal anatomy of the ophthalmic artery in the optic canal. <i>Acta Neurochirurgica</i> , <b>2016</b> , 158, 1343-50	3	9
68	PI-PLC $\beta$ affects Akt activation, cyclin E expression, and caspase cleavage, promoting cell survival in pro-B-lymphoblastic cells exposed to oxidative stress. <i>FASEB Journal</i> , <b>2015</b> , 29, 1383-94	0.9	8
67	Hypoxia-induced down-modulation of PKCepsilon promotes trail-mediated apoptosis of tumor cells. <i>International Journal of Oncology</i> , <b>2010</b> , 37, 719-29	4.4	8
66	Mass spectrometry-based identification of Y745 of Vav1 as a tyrosine residue crucial in maturation of acute promyelocytic leukemia-derived cells. <i>Journal of Proteome Research</i> , <b>2010</b> , 9, 752-60	5.6	8
65	Nuclear PI-PLC $\beta$ and myelodysplastic syndromes: genetics and epigenetics. <i>Current Pharmaceutical Design</i> , <b>2012</b> , 18, 1751-4	3.3	8
64	Nuclear inositide signaling: an appraisal of phospholipase C beta 1 behavior in myelodysplastic and leukemia cells. <i>Advances in Enzyme Regulation</i> , <b>2007</b> , 47, 2-9		8
63	Noradrenergic and cholinergic innervation of the bone marrow. <i>International Journal of Molecular Medicine</i> , <b>2002</b> , 10, 77	4.4	8
62	Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression. <i>Oncotarget</i> , <b>2017</b> , 8, 113033-113033	3.3	8
61	Therapeutic potential of nvp-bkm120 in human osteosarcomas cells. <i>Journal of Cellular Physiology</i> , <b>2019</b> , 234, 10907-10917	7	8
60	Endoscopic endonasal approach to primitive Meckel's cave tumors: a clinical series. <i>Acta Neurochirurgica</i> , <b>2018</b> , 160, 2349-2361	3	8
59	Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy. <i>Mini-Reviews in Medicinal Chemistry</i> , <b>2014</b> ,	3.2	8
58	Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals. <i>Advances in Biological Regulation</i> , <b>2019</b> , 72, 22-40	6.2	7
57	PLC $\alpha$ and PLC $\beta$ selective regulation and cyclin D3 modulation reduced by kinamycin F during k562 cell differentiation. <i>Journal of Cellular Physiology</i> , <b>2015</b> , 230, 587-94	7	7
56	Nuclear Inositides and Inositide-Dependent Signaling Pathways in Myelodysplastic Syndromes. <i>Cells</i> , <b>2020</b> , 9,	7.9	7
55	PI-PLC $\beta$ gene copy number alterations in breast cancer. <i>Oncology Reports</i> , <b>2012</b> , 27, 403-8	3.5	7

54	Inositide signaling: Nuclear targets and involvement in myelodysplastic syndromes. <i>Advances in Enzyme Regulation</i> , <b>2008</b> , 48, 2-9		7
53	Nuclear PI-PLC $\beta$ and Myelodysplastic syndromes: from bench to clinics. <i>Current Topics in Microbiology and Immunology</i> , <b>2012</b> , 362, 235-45	3.3	7
52	Abilities of $\beta$ Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells. <i>Advances in Biological Regulation</i> , <b>2020</b> , 75, 100672	6.2	7
51	GSK-3 $\beta$ Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. <i>Cells</i> , <b>2021</b> , 10,	7.9	7
50	The regulation of insulin secretion via phosphoinositide-specific phospholipase C $\beta$ signaling. <i>Advances in Biological Regulation</i> , <b>2019</b> , 71, 10-18	6.2	7
49	Zafirlukast promotes insulin secretion by increasing calcium influx through L-type calcium channels. <i>Journal of Cellular Physiology</i> , <b>2018</b> , 233, 8701-8710	7	7
48	IPMK and $\beta$ catenin mediate PLC- $\beta$ -dependent signaling in myogenic differentiation. <i>Oncotarget</i> , <b>2016</b> , 7, 84118-84127	3.3	6
47	Quantitative phosphoproteome analysis of embryonic stem cell differentiation toward blood. <i>Oncotarget</i> , <b>2015</b> , 6, 10924-39	3.3	6
46	Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins <b>2006</b> , 28, 127		5
45	Inositides and the nucleus: phospholipase C $\beta$ family localization and signaling activity. <i>Advances in Enzyme Regulation</i> , <b>2000</b> , 40, 83-95		5
44	Recent advances in MDS mutation landscape: Splicing and signalling. <i>Advances in Biological Regulation</i> , <b>2020</b> , 75, 100673	6.2	4
43	The function of PLC $\beta$ 1 in developing mouse mDA system. <i>Advances in Biological Regulation</i> , <b>2020</b> , 75, 100654	6.2	4
42	Location-dependent role of phospholipase C signaling in the brain: Physiology and pathology. <i>Advances in Biological Regulation</i> , <b>2021</b> , 79, 100771	6.2	4
41	The wide and growing range of lamin B-related diseases: from laminopathies to cancer.. <i>Cellular and Molecular Life Sciences</i> , <b>2022</b> , 79, 126	10.3	3
40	Addition of Lenalidomide (LEN) to Azacitidine (AZA) (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes (MDS): A Randomized Phase II Multicenter Study. <i>Blood</i> , <b>2014</b> , 124, 4648-4648	2.2	3
39	Subcellular Localization Relevance and Cancer-Associated Mechanisms of Diacylglycerol Kinases. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	3
38	Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53. <i>Advances in Biological Regulation</i> , <b>2021</b> , 79, 100780	6.2	3
37	Clinical and Molecular Insights in Erythropoiesis Regulation of Signal Transduction Pathways in Myelodysplastic Syndromes and $\beta$ Thalassemia. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3

36	Role of nuclear PLC and PI3K signaling in the development of cancer. <i>Future Lipidology</i> , <b>2007</b> , 2, 303-311	2
35	The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML). <i>Current Signal Transduction Therapy</i> , <b>2007</b> , 2, 246-256	2
34	Sensitization of multidrug resistant human osteosarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase <b>2004</b> , 25, 1599	2
33	Expression of HLA class I antigen and proteasome subunits LMP-2 and LMP-10 in primary vs. metastatic breast carcinoma lesions <b>2004</b> , 25, 1625	2
32	"Modulating Phosphoinositide Profiles as a Roadmap for Treatment in Acute Myeloid Leukemia". <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 678824	5.3 2
31	How Inflammation Pathways Contribute to Cell Death in Neuro-Muscular Disorders. <i>Biomolecules</i> , <b>2021</b> , 11,	5.9 2
30	Inositide-Dependent Nuclear Signalling in Health and Disease. <i>Handbook of Experimental Pharmacology</i> , <b>2020</b> , 259, 291-308	3.2 2
29	Cell signaling pathways in autosomal-dominant leukodystrophy (ADLD): the intriguing role of the astrocytes. <i>Cellular and Molecular Life Sciences</i> , <b>2021</b> , 78, 2781-2795	10.3 2
28	Current therapy and new drugs: a road to personalized treatment of myelodysplastic syndromes. <i>Expert Review of Precision Medicine and Drug Development</i> , <b>2018</b> , 3, 23-31	1.6 1
27	Reply to F. Damm et al. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e388-e389	2.2 1
26	Application of flow cytometry to molecular medicine: Detection of tumor necrosis factor-related apoptosis-inducing ligand receptors in acute myeloid leukaemia blasts. <i>International Journal of Molecular Medicine</i> , <b>2005</b> , 16, 1041	4.4 1
25	Comparison of Two Different Therapeutic Regimens with Azacitidine and Lenalidomide (Combined versus Sequential) in Higher-Risk Myelodysplastic Syndromes. Update of Long-Term Results of a Randomized Phase II Multicenter Study. <i>Blood</i> , <b>2018</b> , 132, 4365-4365	2.2 1
24	Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment. <i>Blood</i> , <b>2010</b> , 116, 233-233	2.2 1
23	Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study. <i>Blood</i> , <b>2010</b> , 116, 4029-4029	2.2 1
22	Role of PLC $\beta$ 1 in the modulation of cell migration and cell invasion in glioblastoma. <i>Advances in Biological Regulation</i> , <b>2021</b> , 100838	6.2 1
21	Prediction of genetic alteration of phospholipase C isozymes in brain disorders: Studies with deep learning. <i>Advances in Biological Regulation</i> , <b>2021</b> , 82, 100833	6.2 1
20	Association of Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes. Final Results of a Randomized Phase II Multicenter Study. <i>Blood</i> , <b>2015</b> , 126, 2871-2871	2.2 1
19	Phospholipase C beta1 (PI-PLC $\beta$ 1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS). <i>FASEB Journal</i> , <b>2020</b> , 34, 15400-15415	6.9 1

18	Lamin B1 Accumulation Effects on Autosomal Dominant Leukodystrophy (ADLD): Induction of Reactivity in the Astrocytes. <i>Cells</i> , <b>2021</b> , 10,	7.9	1
17	The Italian law on body donation: A position paper of the Italian College of Anatomists. <i>Annals of Anatomy</i> , <b>2021</b> , 238, 151761	2.9	1
16	Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53.. <i>Cells</i> , <b>2022</b> , 11,	7.9	1
15	Near-Peer Teaching in Human Anatomy from a Tutors Perspective: An Eighteen-Year-Old Experience at the University of Bologna.. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 19,	4.6	1
14	Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53. <i>Advances in Biological Regulation</i> , <b>2021</b> , 100840	6.2	0
13	Phosphoinositide-specific phospholipase C beta1 signal transduction in the nucleus. <i>Methods in Molecular Biology</i> , <b>2010</b> , 645, 143-64	1.4	0
12	Impact of phospholipase C $\beta$ 1 in glioblastoma: a study on the main mechanisms of tumor aggressiveness.. <i>Cellular and Molecular Life Sciences</i> , <b>2022</b> , 79, 195	10.3	0
11	Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.. <i>Aging</i> , <b>2022</b> , 14, 3365-3386	5.6	0
10	Communication between median and musculocutaneous nerve at the level of cubital fossa - A case report. <i>Translational Research in Anatomy</i> , <b>2018</b> , 11, 1-4	0.8	
9	Sequential Analysis of miRNA Profiling during Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes. <i>Blood</i> , <b>2020</b> , 136, 6-7	2.2	
8	Azacitidine and Lenalidomide in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study and Impact of Cytogenetic Scores and Mutational Status on Long-Lasting Responses. <i>Blood</i> , <b>2020</b> , 136, 45-45	2.2	
7	Negative Prognostic Relevance of a Specific 3-Gene Cluster in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy. <i>Blood</i> , <b>2018</b> , 132, 4347-4347	2.2	
6	Role of Nuclear Inositide Signalling and microRNA Signature in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy. <i>Blood</i> , <b>2016</b> , 128, 5091-5091	2.2	
5	Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study. <i>Blood</i> , <b>2016</b> , 128, 3169-3169 <sup>2.2</sup>		
4	Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients.. <i>Blood</i> , <b>2009</b> , 114, 2384-2384	2.2	
3	Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients. <i>Blood</i> , <b>2012</b> , 120, 1289-1289	2.2	
2	Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients. <i>Blood</i> , <b>2012</b> , 120, 4951-4951	2.2	
1	Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q). <i>Blood</i> , <b>2013</b> , 122, 5227-5227	2.2	

